China's drug administrator approved Shanghai Haohai Biological Technology (SHA:688366) subsidiary Henan Saimei Vision Biotechnology's trifocal intraocular lens.
The product is indicated for vision correction in adult cataract patients and helps improve, near, intermediate, and far vision, according to a Wednesday filing with the Shanghai bourse.